Venetoclax plus gilteritinib is effective in preclinical models of <i>FLT3</i> -mutant BCL11B-a lineage-ambiguous leukemia
Lindsey E. Montefiori(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Qingsong Gao(St. Jude Children's Research Hospital), Marina Konopleva(Albert Einstein College of Medicine), Amit Budhraja(St. Jude Children's Research Hospital), Torsten Haferlach(Martin Luther Christian University), Tanya Khan(St. Jude Children's Research Hospital), Burgess B. Freeman(St. Jude Children's Research Hospital), Joseph T. Opferman(St. Jude Children's Research Hospital), Pradyumna Baviskar(St. Jude Children's Research Hospital), Ilaria Iacobucci(St. Jude Children's Research Hospital), Hongjian Jin(St. Jude Children's Research Hospital), Huimei Wei(St. Jude Children's Research Hospital), William C. Wright(St. Jude Children's Research Hospital), Melissa Johnson(St. Jude Children's Research Hospital), Cyrus Mehr(St. Jude Children's Research Hospital), Emily A. Backhaus(St. Jude Children's Research Hospital), Surbhi Sona(St. Jude Children's Research Hospital), Laura J. Janke(St. Jude Children's Research Hospital), Paul E. Mead(St. Jude Children's Research Hospital), Zhongshan Cheng(St. Jude Children's Research Hospital), Josi Lott(St. Jude Children's Research Hospital), Jamila Moore(St. Jude Children's Research Hospital)
Cited by 7
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k